| 1 | HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer Tissues | Clinical Breast Cancer | 2004 | 603 |
| 2 | Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer | Clinical Breast Cancer | 2009 | 597 |
| 3 | The Global Breast Cancer Burden: Variations in Epidemiology and Survival | Clinical Breast Cancer | 2005 | 491 |
| 4 | Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design | Clinical Breast Cancer | 2009 | 416 |
| 5 | Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab | Clinical Breast Cancer | 2005 | 342 |
| 6 | Cognitive Training for Improving Executive Function in Chemotherapy-Treated Breast Cancer Survivors | Clinical Breast Cancer | 2013 | 272 |
| 7 | Stress Management and Resilience Training (SMART) Program to Decrease Stress and Enhance Resilience Among Breast Cancer Survivors: A Pilot Randomized Clinical Trial | Clinical Breast Cancer | 2011 | 252 |
| 8 | TAILORx: Trial Assigning Individualized Options for Treatment (Rx) | Clinical Breast Cancer | 2006 | 249 |
| 9 | Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer | Clinical Breast Cancer | 2016 | 232 |
| 10 | Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer | Clinical Breast Cancer | 2008 | 227 |
| 11 | Genetic Markers in Triple-Negative Breast Cancer | Clinical Breast Cancer | 2018 | 203 |
| 12 | Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results | Clinical Breast Cancer | 2009 | 200 |
| 13 | Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial | Clinical Breast Cancer | 2021 | 194 |
| 14 | Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes | Clinical Breast Cancer | 2007 | 169 |
| 15 | Review of Factors Influencing Women's Choice of Mastectomy Versus Breast Conserving Therapy in Early Stage Breast Cancer: A Systematic Review | Clinical Breast Cancer | 2018 | 160 |
| 16 | Cancer-related Fatigue in Breast Cancer Survivors: A Review | Clinical Breast Cancer | 2021 | 160 |
| 17 | The Global and Regional Survival Rate of Women With Breast Cancer: A Systematic Review and Meta-analysis | Clinical Breast Cancer | 2019 | 159 |
| 18 | Neoadjuvant Docetaxel in Breast Cancer: 3-Year Survival Results from the Aberdeen Trial | Clinical Breast Cancer | 2002 | 158 |
| 19 | The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer | Clinical Breast Cancer | 2021 | 158 |
| 20 | Serum Interleukin 6, Plasma VEGF, Serum VEGF, and VEGF Platelet Load in Breast Cancer Patients | Clinical Breast Cancer | 2002 | 155 |
| 21 | Incidence and Patterns of Distant Metastases for Patients With Early-Stage Breast Cancer After Breast Conservation Treatment | Clinical Breast Cancer | 2013 | 154 |
| 22 | Molecular Mechanisms of Breast Cancer Metastases to Bone | Clinical Breast Cancer | 2005 | 152 |
| 23 | Results of a Diet/Exercise Feasibility Trial to Prevent Adverse Body Composition Change in Breast Cancer Patients on Adjuvant Chemotherapy | Clinical Breast Cancer | 2008 | 152 |
| 24 | Breast Cancer Chemotherapy-Related Cognitive Dysfunction | Clinical Breast Cancer | 2002 | 150 |
| 25 | Metastasis Suppressor Genes: Basic Biology and Potential Clinical Use | Clinical Breast Cancer | 2003 | 144 |
| 26 | Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden | Clinical Breast Cancer | 2007 | 144 |
| 27 | Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome | Clinical Breast Cancer | 2013 | 144 |
| 28 | Basal Breast Cancer Molecular Subtype Predicts for Lower Incidence of Axillary Lymph Node Metastases in Primary Breast Cancer | Clinical Breast Cancer | 2008 | 142 |
| 29 | The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial | Clinical Breast Cancer | 2010 | 140 |
| 30 | Peripheral Neuropathy with Microtubule-Targeting Agents: Occurrence and Management Approach | Clinical Breast Cancer | 2011 | 140 |
| 31 | Metastatic Breast Cancer: The Treatment Challenge | Clinical Breast Cancer | 2008 | 138 |
| 32 | Adjuvant Chemotherapy for Breast Cancer: Effects on Cerebral White Matter Seen in Diffusion Tensor Imaging | Clinical Breast Cancer | 2008 | 138 |
| 33 | Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer | Clinical Breast Cancer | 2011 | 138 |
| 34 | Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature | Clinical Breast Cancer | 2017 | 138 |
| 35 | Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252 | Clinical Breast Cancer | 2005 | 137 |
| 36 | Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer | Clinical Breast Cancer | 2003 | 136 |
| 37 | Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer | Clinical Breast Cancer | 2014 | 135 |
| 38 | Alarming Burden of Triple-Negative Breast Cancer in India | Clinical Breast Cancer | 2018 | 134 |
| 39 | Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis | Clinical Breast Cancer | 2018 | 134 |
| 40 | CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer | Clinical Breast Cancer | 2010 | 132 |
| 41 | Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database | Clinical Breast Cancer | 2010 | 131 |
| 42 | A Novel Approach Toward Development of a Rapid Blood Test for Breast Cancer | Clinical Breast Cancer | 2003 | 130 |
| 43 | Effects of Tai Chi Chuan on Insulin and Cytokine Levels in a Randomized Controlled Pilot Study on Breast Cancer Survivors | Clinical Breast Cancer | 2011 | 128 |
| 44 | Radiomics Analysis on Ultrasound for Prediction of Biologic Behavior in Breast Invasive Ductal Carcinoma | Clinical Breast Cancer | 2018 | 126 |
| 45 | Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories | Clinical Breast Cancer | 2004 | 124 |
| 46 | Treatment of Metastatic Breast Cancer with Trastuzumab and Vinorelbine During Pregnancy | Clinical Breast Cancer | 2005 | 124 |
| 47 | Aromatase Inhibitor–Associated Arthralgia and/or Bone Pain: Frequency and Characterization in Non–Clinical Trial Patients | Clinical Breast Cancer | 2007 | 124 |
| 48 | Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis | Clinical Breast Cancer | 2010 | 124 |
| 49 | E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer | Clinical Breast Cancer | 2003 | 123 |
| 50 | Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis | Clinical Breast Cancer | 2017 | 122 |